TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00645268
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.
Study: NCT00874731
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: A single oral dose of placebo (10 x placebo tablets) was given on Day 1.
Study: NCT00458081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once per day + slightly reduced calorie diet
Study: NCT00479882
Drug: Comparator: simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00479882
Drug: MK-0524A
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet
Study: NCT00479882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00479882
Drug: MK-0524B
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00056875
Drug: recombinant human keratinocyte growth factor
Normalized name: Recombinant human keratinocyte growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00584584
Drug: QAX576
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00584584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03583658
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: lozenges Route of administration: oromucosal
Study: NCT02123290
Drug: DSM265 400mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02123290
Drug: DSM265 xmg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of DSM265 to be determined based on the results of the first cohort
Study: NCT02123290
Drug: DSM265 ymg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of DSM265 to be determined based on the results of the second cohort
Study: NCT03929419
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal spray containing placebo solution
Study: NCT02367014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
Study: NCT02027363
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: maintenance with apecitabine，1,000 mg/m2 twice a day， days1-15，every 3 weeks，until progression, unacceptable toxicity, or patient withdrawal.
Study: NCT00968825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Dose E) applied topically at Baseline (Day 0) to the lateral canthal lines
Study: NCT04161729
Drug: Isotonic saline 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline 0.9% 100ml over a 15-min period before induction of anesthesia and thereafter continuous i.v. infusion until surgery completion in dosage identical to magnesium sulfate group.
Study: NCT03882177
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, administered orally
Study: NCT03882177
Drug: Rifafour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (isoniazid, rifampin, pyrazinamide, and ethambutol) tablets, administered orally
Study: NCT00376077
Drug: Methylprednisolone and IVIG
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination therapy (IV MP (Solu-Medrol®, Upjohn) 30 mg/kg (max. 1 g) over 1 hour followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose
Study: NCT00376077
Drug: Placebo and IVIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose
Study: NCT00245908
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00558844
Drug: Arikayce™ 560 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arikayce™ at 560 mg~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Study: NCT00558844
Drug: Arikayce™ 140 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Study: NCT00558844
Drug: Placebo for 70 mg / 140 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Study: NCT01484600
Drug: REGN668: Injection Rate 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive REGN668 via SC injection
Study: NCT01484600
Drug: REGN668: Injection Rate 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive study drug via alternate delivery (if necessary)
Study: NCT01301040
Drug: epirubicin, cyclophosphamide, docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.~* Treatment Arm 2: TC - docetaxel (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
Study: NCT03921099
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ascorbic acid is an antioxidant that is expected to prevent nephrotoxicty induced by Vancomycin.
Study: NCT03586934
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen Tablet
Study: NCT03586934
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib Tablet
Study: NCT03586934
Drug: Celecoxib 400 mg
Normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib Tablet
Study: NCT03586934
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketorolac injection
Study: NCT03586934
Drug: Acetaminophen Injectable Product
Normalized name: acetaminophen Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen injection
Study: NCT03586934
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: meloxicam tablet
Study: NCT03364075
Drug: Placebo Treatment
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule BID for two weeks
Study: NCT01427725
Drug: Lipacreon
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study was an observational study and no intervention was specified
Study: NCT00504465
Drug: dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01962532
Drug: Part 1: JNJ-42756493
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42756493 dose escalation starting at dose of 2 mg orally daily for 21-day cycles and 28 day cycles Intermitting dosing regimen (7 days on and 7 days off) up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.
Study: NCT00522821
Drug: intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Adults: 600 mg/kg bodyweight every 3 weeks~* Children: 800 mg/kg bodyweight every 3 week
Study: NCT00522821
Drug: antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.~* Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid.
Study: NCT02728921
Drug: 5% Albumin infusion 30 min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.
Study: NCT03179631
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10, 20 mg/kg
Study: NCT00692055
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 375 mg
Study: NCT00919893
Drug: Cernilton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.
Study: NCT00919893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.
Study: NCT02572336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a THR-18 lookalike, to be administered with tPA.
Study: NCT00247624
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 20 mg every morning for 9 weeks
Study: NCT00247624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every night for 8 weeks
Study: NCT00562068
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00850044
Drug: ABT-450
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules,QD, one dose, see Arm Descriptions for more information
Study: NCT00850044
Drug: placebo for ABT-450
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, QD, one dose
Study: NCT01343862
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sugar pill will be given to those patients randomized to the control group at 48-72 hours after moderate brain injury
Study: NCT00930670
Drug: Rosuvastatin-ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months
Study: NCT00147589
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01755572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
Study: NCT00672737
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil was administered as a computer-controlled infusion, targeting two different effect site concentrations, 1 and 2 mcg/mL, in randomized order.
Study: NCT01591460
Drug: ribavirin (Copegus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
Study: NCT01591460
Drug: ribavirin (Copegus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg or 1200 mg orally once a day for 4 weeks
Study: NCT04215393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the second stage, subjects will be receive Conbercept eys drop or a placebo.
Study: NCT01940133
Drug: PQR309
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing will be orally, once a day for the duration of the trial.
Study: NCT01022112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01803282
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Study: NCT03609892
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsulesTID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
Study: NCT01810458
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
Study: NCT01810458
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
Study: NCT04407741
Drug: SHR2554+SHR1701
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554: recommended dose from phase I trial, PO, twice a day. SHR1701: 30mg/kg, IV, over 30 minutes
Study: NCT04407741
Drug: SHR1701
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR1701: 30mg/kg, IV, over 30 minutes
Study: NCT03072082
Drug: Danlou Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine \& Danlou Tablet
Study: NCT03072082
Drug: DanLou Tablet placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine \& placebo (for Danlou Tablet)
Study: NCT02069119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01741103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one by mouth daily for 12 weeks
Study: NCT03014479
Drug: Daily DPP-4 inhibitor
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin
Study: NCT02644278
Drug: VX-984 120 mg + PLD 40 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received VX-984 orally 120 milligram (mg) orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 120 mg in combination with pegylated liposomal doxorubicin (PLD) 40 milligram per square meter (mg/m\^2) administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
Study: NCT04357002
Drug: vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Study: NCT02489968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04357002
Drug: vaginal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Study: NCT02618057
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO prednisolone, 1 mg/kg/day, for 5 days
Study: NCT01350622
Drug: Diclofenac hydroxyethylpyrrolidine
Normalized name: diclofenac hydroxyethylpyrrolidine 1.292 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: active treatment oral Diclofenac and PENNSAID placebo. Patients will take a single 50mg dose of oral diclofenac and will apply 40 drops of placebo lotion (2.3% DMSO) to the affected ankle once.
Study: NCT03435302
Drug: High-Dose IFN-a2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon belongs to the large class of glycoproteins known as cytokines.
Study: NCT01593787
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, 200 mg, 400 mg tablets.
Study: NCT02644278
Drug: VX-984 240 mg + PLD 40 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received VX-984 orally 240 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 240 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
Study: NCT03993262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
Study: NCT03468478
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm: mycophenolate combined to regular tacrolimus
Study: NCT02537210
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be prescribed placebo 5 capsules daily for 12 months
Study: NCT03572647
Drug: Eritromax
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
Study: NCT03572647
Drug: Eprex
Normalized name: Eprex
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
Study: NCT03211234
Drug: 2.0 mg DE-122 Injectable Solution + Lucentis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.
Study: NCT03418935
Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
Study: NCT02666963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03881059
Drug: BMS-986165 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive BMS-986165 dose B QD.
Study: NCT00954889
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (tamsulosin 0.2mg + placebo)/day Posology: two tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
Study: NCT00449618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo on awakening versus bedtime
Study: NCT01367288
Drug: Zometa + Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg (in a 15 min. infusion) every 3 weeks for a total of 8 injections
Study: NCT01367288
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks (+/- 2 days)
Study: NCT00114153
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02644278
Drug: VX-984 480 mg + PLD 40 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received VX-984 orally 480 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 480 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
Study: NCT01666587
Drug: Prostaglandin inhibitor (Ibuprophen)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02185222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
Study: NCT04180488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study: NCT02393300
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
Study: NCT00214916
Drug: intensive insulin therapy (Actrapid IV to normoglycemia)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)
Study: NCT02961803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no